Results 1 to 10 of about 805,984 (229)

Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo [PDF]

mAbs, 2021
Albumin has a serum half-life of 3 weeks in humans. This feature can be used to improve the pharmacokinetics of shorter-lived biologics. For instance, an albumin-binding domain (ABD) can be used to recruit albumin.
Simone Mester, Mitchell Evers, Saskia Meyer, Jeannette Nilsen, Victor Greiff, Inger Sandlie, Jeanette Leusen, Jan Terje Andersen   +7 more
doaj   +7 more sources

Measurement of extended half-life recombinant FVIII molecules: In vitro and ex vivo evidence of relevant assay discrepancies

Research and Practice in Thrombosis and Haemostasis, 2023
Extended half-life recombinant FVIII products (EHL-rFVIIIs) have been engineered to improve the pharmacokinetic profile of FVIII, enabling better hemostatic protection with a reduced number of injections in persons with hemophilia. Previous studies showed several discrepancies in FVIII activity (FVIII:C) measurements for EHL-rFVIIIs comparing one-stage
Lancellotti, Stefano, Sacco, Monica, Tardugno, Maira, Mancuso, Maria Elisa, De Cristofaro, Raimondo   +4 more
openaire   +3 more sources

A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life [PDF]

mAbs, 2015
Immunoglobulin G (IgG) has an unusually long serum half-life in comparison to proteins of a similar size. It is well-known that this phenomenon is due to IgG's ability to bind the neonatal Fc receptor (FcRn) in a pH-dependent manner. FcRn binding properties can vary among IgGs, resulting in altered in vivo half-lives, and therefore it would be ...
Souders, Colby A, Nelson, Stuart C, Wang, Yang, Crowley, Andrew R, Klempner, Mark S, Thomas, William   +5 more
openaire   +3 more sources

QSPR modelling ofin vitrodegradation half-life of acyl glucuronides

Xenobiotica, 2018
Acyl glucuronidation is an important Phase II biotransformation, which is an efficient detoxification mechanism for the metabolism of carboxylic acid group-containing drugs. However, the reactivity of acyl glucuronide (AG) metabolites associated with short half-lives may be an indication of idiosyncratic drug toxicity.The degradation half-lives of AGs ...
Gulcin Tugcu, Hande Sipahi
openaire   +3 more sources

Control of c-myc mRNA half-life in vitro by a protein capable of binding to a coding region stability determinant. [PDF]

Genes & Development, 1992
Polysome-associated c-myc mRNA is degraded relatively rapidly in cells and in an in vitro mRNA decay system containing extracts from cultured mammalian cells. Using this system, a competition/screening assay was devised to search for factors that bind to specific regions of polysome-associated c-myc mRNA and thereby alter its half-life.
P L, Bernstein, D J, Herrick, R D, Prokipcak, J, Ross   +3 more
openaire   +3 more sources

PEGylation Extends Circulation Half-Life While Preserving In Vitro and In Vivo Activity of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1)

PLoS ONE, 2012
Excess proteolytic activity of matrix metalloproteinases (MMPs) contributes to the development of arthritis, cardiovascular diseases and cancer progression, implicating these enzymes as therapeutic targets. While many small molecule inhibitors of MMPs have been developed, clinical uses have been limited, in part by toxicity and off-target effects ...
Jyotica Batra, Jessica Robinson, Christine Mehner, Alexandra Hockla, Erin Miller, Derek C Radisky, Evette S Radisky   +6 more
openaire   +5 more sources

Improved Biodistribution and Extended Serum Half-Life of a Bacteriophage Endolysin by Albumin Binding Domain Fusion

Frontiers in Microbiology, 2018
The increasing number of multidrug-resistant bacteria intensifies the need to develop new antimicrobial agents. Endolysins are bacteriophage-derived enzymes that degrade the bacterial cell wall and hold promise as a new class of highly specific and ...
Johan Seijsing, Anna M. Sobieraj, Nadia Keller, Yang Shen, Annelies S. Zinkernagel, Martin J. Loessner, Mathias Schmelcher   +6 more
doaj   +2 more sources

Fusion of a short peptide that binds immunoglobulin G to a recombinant protein substantially increases its plasma half-life in mice. [PDF]

PLoS ONE, 2014
We explore a strategy to substantially increase the half-life of recombinant proteins by genetic fusion to FcIII, a 13-mer IgG-Fc domain binding peptide (IgGBP) originally identified by DeLano and co-workers at Genentech [DeLano WL, et al. (2000) Science
Jonathan T Sockolosky, Saul Kivimäe, Francis C Szoka   +2 more
doaj   +2 more sources

Evaluation of Alectinib Metabolic Stability in HLMs Using Fast LC-MS/MS Method: In Silico ADME Profile, P450 Metabolic Lability, and Toxic Alerts Screening

Pharmaceutics, 2023
Alectinib, also known as Alecensa®, is prescribed for the therapeutic treatment of individuals diagnosed with metastatic non-small cell lung cancer (NSCLC) who have a specific genetic mutation referred to as anaplastic lymphoma kinase (ALK) positivity ...
Mohamed W. Attwa, Haitham AlRabiah, Gamal A. E. Mostafa, Adnan A. Kadi   +3 more
doaj   +1 more source

Assessment of In Silico and In Vitro Selpercatinib Metabolic Stability in Human Liver Microsomes Using a Validated LC-MS/MS Method

Molecules, 2023
Selpercatinib (SLP; brand name Retevmo®) is a selective and potent RE arranged during transfection (RET) inhibitor. On 21 September 2022, the FDA granted regular approval to SLP (Retevmo, Eli Lilly, and Company).
Mohamed W. Attwa, Haitham AlRabiah, Gamal A.E. Mostafa, Ahmed H. Bakheit, Adnan A. Kadi   +4 more
doaj   +1 more source